Ivosenib 250 Mg (Ivosidenib) – 60 Tablets

Ivosenib 250 Mg (Ivosidenib) is an advanced targeted therapy for the treatment of acute myeloid leukemia (AML) and cholangiocarcinoma in patients with an isocitrate dehydrogenase-1 (IDH1) mutation. Containing Ivosidenib, Ivosenib 250 mg specifically inhibits the mutated IDH1 enzyme, which is responsible for the abnormal production of an oncometabolite that drives cancer growth. This medication provides a critical option for patients with IDH1-mutated AML and cholangiocarcinoma, offering a targeted approach that can lead to remission and improve survival rates.

Ivosenib 250 mg is indicated for the treatment of:

• IDH1-Mutated Acute Myeloid Leukemia (AML): Ivosenib is used in adult patients with relapsed or refractory AML who have a confirmed IDH1 mutation. It provides a targeted treatment option that addresses the specific genetic driver of the disease.
• IDH1-Mutated Cholangiocarcinoma: Ivosenib 250 is also indicated for the treatment of patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation, offering a targeted approach to managing this rare and challenging cancer.

Product Feature:

You will have the ability to order easily and pay the best price if you use Unit Pharmacy Website for buying Ivosenib 250 Mg (Ivosidenib) medicine.